RU2018101722A - Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии - Google Patents

Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии Download PDF

Info

Publication number
RU2018101722A
RU2018101722A RU2018101722A RU2018101722A RU2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A
Authority
RU
Russia
Prior art keywords
salmonella
seq
additional
protein
cancer
Prior art date
Application number
RU2018101722A
Other languages
English (en)
Russian (ru)
Other versions
RU2018101722A3 (enExample
Inventor
Хайнц Лубенау
Original Assignee
Факсимм Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Факсимм Аг filed Critical Факсимм Аг
Publication of RU2018101722A publication Critical patent/RU2018101722A/ru
Publication of RU2018101722A3 publication Critical patent/RU2018101722A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2018101722A 2015-06-18 2016-06-16 Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии RU2018101722A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15001803.4 2015-06-18
EP15001803 2015-06-18
PCT/EP2016/001004 WO2016202459A1 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Publications (2)

Publication Number Publication Date
RU2018101722A true RU2018101722A (ru) 2019-07-18
RU2018101722A3 RU2018101722A3 (enExample) 2019-12-10

Family

ID=53476620

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018101722A RU2018101722A (ru) 2015-06-18 2016-06-16 Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии

Country Status (19)

Country Link
US (2) US10905752B2 (enExample)
EP (2) EP3310379B1 (enExample)
JP (1) JP6947649B2 (enExample)
KR (2) KR20250024816A (enExample)
CN (1) CN107995868B (enExample)
AU (1) AU2016278588B2 (enExample)
BR (1) BR112017027378A2 (enExample)
CA (1) CA2989247C (enExample)
DK (1) DK3310379T3 (enExample)
ES (2) ES2760699T3 (enExample)
HU (1) HUE046631T2 (enExample)
IL (1) IL256076A (enExample)
LT (1) LT3310379T (enExample)
MX (1) MX2017016183A (enExample)
PL (2) PL3310379T3 (enExample)
RU (1) RU2018101722A (enExample)
SI (1) SI3310379T1 (enExample)
WO (1) WO2016202459A1 (enExample)
ZA (1) ZA201708439B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3534935A1 (en) * 2016-11-04 2019-09-11 Vaximm AG Wt1 targeting dna vaccine for combination therapy
KR20190117603A (ko) 2017-02-17 2019-10-16 백심 아게 신규 vegfr-2 표적화 면역요법상 접근법
SG11201908528UA (en) * 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
AU2021208400A1 (en) * 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
BR112014015706A2 (pt) 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
SG11201500054QA (en) * 2012-07-05 2015-03-30 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
MX375442B (es) * 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
SG11201506052PA (en) * 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
DK2988762T3 (en) * 2013-04-25 2018-07-16 Vaximm Ag SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1
PL3082850T3 (pl) * 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu
KR20190117603A (ko) * 2017-02-17 2019-10-16 백심 아게 신규 vegfr-2 표적화 면역요법상 접근법
SG11201908528UA (en) * 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
MX2017016183A (es) 2018-06-19
PL3626262T3 (pl) 2025-02-17
SI3310379T1 (sl) 2020-02-28
ZA201708439B (en) 2021-05-26
CA2989247C (en) 2023-10-17
CN107995868A (zh) 2018-05-04
JP2018517419A (ja) 2018-07-05
CN107995868B (zh) 2021-07-13
US20180250345A1 (en) 2018-09-06
WO2016202459A1 (en) 2016-12-22
AU2016278588B2 (en) 2022-03-31
EP3626262A1 (en) 2020-03-25
HK1252435A1 (en) 2019-05-24
DK3310379T3 (da) 2019-12-16
JP6947649B2 (ja) 2021-10-13
LT3310379T (lt) 2019-12-27
ES2760699T3 (es) 2020-05-14
US20210077605A1 (en) 2021-03-18
EP3310379A1 (en) 2018-04-25
KR20250024816A (ko) 2025-02-19
KR20180037948A (ko) 2018-04-13
IL256076A (en) 2018-01-31
CA2989247A1 (en) 2016-12-22
PL3310379T3 (pl) 2020-03-31
ES2994561T3 (en) 2025-01-27
RU2018101722A3 (enExample) 2019-12-10
EP3626262C0 (en) 2024-10-23
EP3626262B1 (en) 2024-10-23
HUE046631T2 (hu) 2020-03-30
AU2016278588A1 (en) 2017-12-21
US10905752B2 (en) 2021-02-02
EP3310379B1 (en) 2019-11-06
BR112017027378A2 (pt) 2018-08-28

Similar Documents

Publication Publication Date Title
Liu et al. Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy
Sivanandam et al. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds
Fu et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects
Skeate et al. TNFSF14: LIGHTing the way for effective cancer immunotherapy
Weichselbaum The 46th David A. Karnofsky Memorial Award lecture: oligometastasis—from conception to treatment
Kuryk et al. Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
Das et al. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
JP6325534B2 (ja) 膵臓癌患者用ｄｎａワクチン
RU2016129044A (ru) Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака
Farrera-Sal et al. Evolving status of clinical immunotherapy with oncolytic adenovirus
Yamano et al. Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model
Wang et al. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity
Silva et al. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo
JP2018517419A5 (enExample)
JP2011500718A5 (enExample)
Silva-Pilipich et al. Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer
JP2020511139A5 (enExample)
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Wang et al. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
Deng et al. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy
Zhao et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response
Shakiba et al. Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response
BR112021001117A2 (pt) células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
Lyu et al. Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects
Nguyen et al. A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20210817